Product Description
An orally bioavailable, small-molecule, dihydrogen phosphate prodrug of the pyrazoloquinazoline Aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide (AZD1152-HQPA) with potential antineoplastic activity. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/barasertib)
Mechanisms of Action: AURK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 2: Acute Myeloid Leukemia|Diffuse Large B-Cell Lymphoma
Phase 1: Leukemia|Acute Myeloid Leukemia|Oncology Solid Tumor Unspecified|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00926731 |
LDAC | P1 |
Completed |
Acute Myeloid Leukemia |
2010-08-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT01019161 |
D1531C00012 | P1 |
Completed |
Acute Myeloid Leukemia |
2010-06-01 |
2019-03-19 |
Treatments |
|
NCT00497991 |
D1531C00007 | P1 |
Completed |
Acute Myeloid Leukemia |
2009-10-01 |
2019-03-21 |
Treatments |
|
NCT00530699 |
D1531C00008 | P1 |
Completed |
Acute Myeloid Leukemia |
2009-08-01 |
2019-03-21 |
Treatments |
|
NCT00338182 |
D1531C00002 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-06-06 |
2019-03-21 |
||
NCT00497731 |
D1531C00001 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2008-06-01 |
2019-03-21 |
Treatments |
|
JapicCTI-080508 |
JapicCTI-080508 | P1 |
Completed |
Leukemia |
None |
|||
NCT00497679 |
D1531C00003 | P1 |
Terminated |
Other |
None |
2019-03-21 |
Treatments |
|
2010-022812-37 |
AZD1152 in diffuse large B-cell lymphoma | P2 |
Completed |
Diffuse Large B-Cell Lymphoma |
2013-09-09 |
2022-03-13 |
Treatments |
|
NCT01354392 |
ORH/PID/6265 | P2 |
Completed |
Diffuse Large B-Cell Lymphoma |
2013-09-01 |
2019-03-19 |
Treatments |
|
2009-010114-30 |
2009-010114-30 | P2 |
Terminated |
Acute Myeloid Leukemia |
2012-04-26 |
2022-03-13 |
Treatments |
|
JapicCTI-090957 |
JapicCTI-090957 | P2 |
Completed |
Acute Myeloid Leukemia |
None |
|||
NCT00952588 |
SPARK-AML1 | P3 |
Completed |
Acute Myeloid Leukemia |
2011-06-01 |
2019-03-18 |
Treatments |